📄 AVALON GLOBOCARE CORP.

Avalon GloboCare Corp. is developing an exosome isolation system and plans to develop therapeutic products as a byproduct. The company is in the early stage of production and intends to file investigational new drug applications for cell-based therapies and diagnostic systems. It also contemplates potential mergers and acquisitions to obtain additional products, personnel, and technologies. Offering: $4,200,000 at $4,200,000 valuation Key risk: Product candidates require substantial time and resources to develop with no guarantee of success. Proceeds: mergers and acquisitions, debt repayment, laboratory and clinical trials, general and administrative expenses, working capital

Avalon GloboCare Corp. is developing an exosome isolation system and plans to develop therapeutic products as a byproduct. The company is in the early stage of production and intends to file investigational new drug applications for cell-based therapies and diagnostic systems. It also contemplates potential mergers and acquisitions to obtain additional products, personnel, and technologies.